Company news

Viatris Inc. news in 2026

Viatris Inc.'s news releases, calls and decks from 2026, newest first.

View company

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

October 16, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

October 8, 2026

Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

October 5, 2026

Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

September 29, 2026

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

September 16, 2026

Viatris Reports Second-Quarter 2026 Financial Results

August 6, 2026

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

July 29, 2026

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

July 1, 2026

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

June 29, 2026

Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

June 16, 2026

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

May 18, 2026

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

May 7, 2026

Viatris Announces Chief Financial Officer Transition

May 4, 2026

Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More

May 1, 2026

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

May 1, 2026

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

April 13, 2026

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

April 10, 2026

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

March 22, 2026

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

March 18, 2026

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

March 11, 2026

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

February 25, 2026

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

February 25, 2026

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

February 24, 2026

Halozyme reports full year 2025 record revenue of $1.4 billion and reiterates strong 2026 Financial Guidance

February 17, 2026

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

February 3, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

February 3, 2026

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

January 19, 2026

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

January 8, 2026

Calls in 2026

Decks in 2026